PEOPLE

Adrian Bellamy, retired chairman and CEO of the DFS Group Ltd., has been elected to the board of directors of Shaman Pharmaceuticals (S. San Francisco, CA). Mr. Bellamy currently serves on the board of directors of Airport Group International, The Body Shop International, The Gap, Gucci Group, Paragon Trade Brands, and Williams-Sonoma.

Jerry Caulder has been named chairman of the board of Myelos Neurosciences (San Diego, CA). From 1984-1998, Dr. Caulder served as Mycogen's president and CEO and as chairman and chairman emeritus of its board of directors.

Avigen, Inc. (Alameda, CA) has announced the appointment of Kenneth Chahine as director of intellectual property. Prior to joining Avigen, Dr. Chahine worked at the patent law firm of Madson and Metcalf in Salt Lake City from 1994 to the present.

Biogen (Cambridge, MA) has appointed Larry Gatlin as director of pharmaceutical and analytical development. Dr. Gatlin joins Biogen after a 10-year career with Glaxo Wellcome, where he most recently served as section head in the pharmaceutics department.

NeoPharm Inc. (Bannockburn, IL) has named lames Hussey as president, CEO, and director. He succeeds William C. Govier, who recently retired from the company and will serve as a consultant. Mr. Hussey cofounded and was named CEO and director of Physician's Quality Care, a physician-owned managed care organization.

DepoTech Corp. (San Diego) has announced the resignation of cofounder and chief scientific officer Sinil Kim. His responsibilities will be assumed by Sheldon A. Schaffer, vice president of pharmaceutical development. Also, Linda J. Paradiso has resigned as vice president of clinical development to pursue other interests.



Jay Lichter has been appointed to the newly created position of vice president of pharmacogenomics for Genset (Paris). Previously, Dr. Lichter was the senior director of pharmacogenomics and diagnostics at Sequana

Therapeutics. He will be based in La Jolla, CA, and will become a member of the Genset-Abbott Alliance Business Committee. Matrix Pharmaceutical (Fremont, CA) has announced that Bradley G. Lorimier has been appointed to its board of directors. Mr. Lorimier was senior vice president and a director of Human Genome Sciences from 1994-1997.

Cytogen Corp. (Princeton, NJ) has announced that William C. Mills III, a member of the board of directors, has assumed the office of chairman of the board. Mr. Mills is a general partner of The Venture Capital Fund of New England. Also, John E. Bagalay Ir., a member of the board of directors, will serve as interim president and CEO in addition to his duties as CFO. Thomas J. McKearn has relinquished his positions as chairman, president, and CEO of the company, as had been announced previously, and is returning to a scientific role in the company.

Daniel J. Paracka has resigned as chairman of the board and a director of Lidak Pharmaceuticals (La Jolla, CA). William N. Jenkins, a founding director, has been appointed chairman in his place.



Chris Sander has been named chief information science officer of Millennium Pharmaceuticals' (Cambridge, MA) newest spinout effort, Millennium Information (MInfo). Dr. Sander comes to Millennium from the

European Bioinformatics Institute, a branch of the European Molecular Biology Laboratory. Dr. Sander was instrumental in forming the department of biocomputing at EMBL in Heidelberg, and in founding EMBnet, a network for molecular biologists in Europe. Dr. Sander is the inventor of GeneQuiz, a functional genomics software. Currently, he is an executive editor of the journal Bioinformatics and scientific advisor to the German Human Genome Project.

Visible Genetics (Toronto, Ontario, Canada) has announced that Chalom Sayada has joined the company as vice president of European business development. Dr. Sayada joins the company from ACT GENE in Paris, where he served as president.

VIMRX Pharmaceuticals (Wilmington, DE) has announced the appointment of Victor W. Schmitt to its board of directors. Mr. Schmitt is currently president of venture management at Baxter Healthcare.

James Warren has been named CFO and treasurer at Aquila Biopharmaceuticals (Worcester, MA). Mr. Warren had been a vice president and controller of Genzyme Corp.

Aronex Pharmaceuticals (The Woodlands, TX) has announced the appointment of Anthony H. Williams as vice president of medical affairs, Europe. Dr. Williams has held positions at Medeva plc, Marion Merrell Dow (now Hoechst Marion Roussel), and Glaxo Group Research.



Chiron (Emeryville, CA) has promoted Lewis T. ("Rusty") Williams to the newly created position of chief scientific officer. Dr. Williams, who remains president of Chiron Technologies, will oversee all Chiron's research

activities including therapeutics, vaccines, and some aspects of diagnostics. He joined Chiron in 1994 as a senior vice president and president of Chiron Technologies.

TIME IS MONEY **SAVE BOTH**

DNA SEQUENCING \$1.25 per base pair

PRIMERS \$1.00 per base

We Also Offer:

ssDNA Sequencing	\$50 / Run
Peptide Synthesis	\$15.50/ A.A.
Amino Acid Analysis	\$84 / Sample
Protein Sequencing	\$ 30 / A.A.*
* plus setup charg	je

For More Information Call Us Today

800-343-8998

http://www.ssr4dna.com

Southwest Scientific Resources Inc.

*DEPENDABLE * ACCURATE* *AFFORDABLE*

